PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2011 | 67 | 01 |

Tytuł artykułu

Nowe kierunki w leczeniu przeciwnowotworowym. Wykorzystanie nanotechnologii

Warianty tytułu

EN
Novel approaches to cancer therapy. The use of nanotechnologies

Języki publikacji

PL

Abstrakty

EN
Neoplastic diseases are increasingly better known. However, their treatment still proves difficult in both human and veterinary medicine. Commonly used cytostatics have numerous limitations due to their high toxicity, nonspecific distribution and numerous adverse effects. Nanobiotechnology is a new method used in cancer therapy. This paper describes the potential use of nanoparticles in cancer treatment. Owing to their specific ability to act as drug carriers, they can be applied in both active and passive targeting. There are several registered nanoparticle-cytostatic combinations, and many others are undergoing clinical trials. Among others, liposomes and other lipid-based particles, drug-connected polymers, polymer microspheres, micelles and dendrimers are used.

Wydawca

-

Rocznik

Tom

67

Numer

01

Opis fizyczny

s.34-37,bibliogr.

Twórcy

autor
  • Katedra Chorób Małych Zwierząt z Kliniką, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego, ul.Nowoursynowska 159, 02-276 Warszawa
autor

Bibliografia

  • 1. Alexis F., Rhee J. W., Richie J. P., Radovic-Moreno A. F., Langer R., Farokhzad O. C.: New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008, 26, 74-85.
  • 2. Brigger I., Dubernet C., Couvreur P.: Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002, 54, 631-651.
  • 3. Chen B. A., Dai Y. Y., Wang X. M., Zhang R. Y., Xu W. L., Shen H. L., Gao F., Sun Q., Deng X. J., Ding J. H., Gao C., Sun Y. Y., Cheng J., Wang J., Zhao G., Chen N. N.: Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells. Int. J. Nanomedicine 2008, 3, 343-350.
  • 4. Cho K., Wang X., Nie S., Chen Z. G., Shin D. M.: Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res. 2008, 14, 1310-1316.
  • 5. Donald V. Mac: Chemotherapy: Managing side effects and safe handling. Can Vet J. 2009, 50, 665-668.
  • 6. Farokhzad O. C., Langer R.: Impact of nanotechnology on drug delivery. ACS Nano. 2009, 3, 16-20.
  • 7. Gibbs D. D., Pyle L., Allen M., Vaughan M., Webb A., Johnston S. R., Gore M. E.: A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br. J. Cancer. 2002, 86, 1379-1384.
  • 8. Gil P. R., Parak W. J.: Composite nanoparticles take aim at cancer. ACS Nano. 2008, 2, 2200-2205.
  • 9. Guo D., Wu C., Song W., Jiang H., Wang X., Chen B.: Effect of colloidal gold nanoparticles on cell interface and their enhanced intracellular uptake of arsenic trioxide in leukemia cancer cells. Nanosci Nanotechnol. 2009, 9, 4611-4617.
  • 10. Huxley D. W., Neal Mauldin N., Shiomitsu K., Mauldin G. E.: Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy. Can. Vet. J. 2010, 51, 293-300.
  • 11. James N. D., Coker R. J., Tomlinson D., et al.: Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin. Oncol. 1994, 6, 294-296.
  • 12. Kang B., Mackey M. A., El-Sayed M. A.: Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. Am. Chem. Soc. 2010, 132, 1517-1519.
  • 13. Kim D., Lee E. S., Oh K. T., Gao Z. G., Bae Y. H.: Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer. 2009, 9, 399.
  • 14. Kubik T., Bogunia-Kubik K., Sugisaka M.: Nanotechnology on duty in medical applications. Curr Pharm Biotechnol. 2005, 6, 17-33.
  • 15. Langer R., Tirrell D. A.: Designing materials for biology and medicine. Nature. 2004, 428(6982), 487-492.
  • 16. Liu P., Wang B., Li J., Qiao W.: Multi-anticancer drugs encapsulated in the micelle: A novel chemotherapy to cancer. Medical Hypotheses 2008, 71, 379-381.
  • 17. Luo Y., Bernshaw N. J., Lu Z. R., Kopecek J., Prestwich G. D.: Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates. Pharmac. Res. 2002, 19, 396-402.
  • 18. Maeda H., Wua J., Sawaa T., Matsumurab Y., Horic K.: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
  • 19. Onuma K., Sato Y., Ogawara S., Shirasawa N., Kobayashi M., Yoshitake J., Yoshimura T., Iigo M., Fujii J., Okada F.: Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am. J. Pathol. 2009, 175, 2171-2183.
  • 20. Otsukaa H., Nagasaki Y., Kataokac K.: PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug. Deliv. Rev. 2003, 55, 403-419.
  • 21. Paciotti G. F., Myer L., Weinreich D., Goia D., Pavel N., Mc Laughlin R. E., Tamarkin L.: Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004, 11, 169-183.
  • 22. Petrelli N. J., Winer E. P., Brahmer J., Dubey S., Smith S., Thomas C., Vahdat L. T., Obel J., Vogelzang N., Markman M., Sweetenham J. W., Pfister D., Kris M. G., Schuchter L. M., Sawaya R., Raghavan D., Ganz P. A., Kramer B.: Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J. Clin. Oncol. 2009, 27, 6052-6069.
  • 23. Prabaharan M., Grailer J. J., Pilla S., Steeber D. A., Gong S.: Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials. 2009, 30, 6065-6075.
  • 24. Sajja H. K., East M. P., Mao H., Wang Y. A., Nie S., Yang L.: Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr. Drug. Discov. Technol. 2009, 6, 43-51.
  • 25. Sinha R., Kim G. J., Nie S., Shin D. M.: Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5, 1909-1917.
  • 26. Slepushkin V. A., Simőes S., Dazin P., Newman M. S., Guo L. S., Pedroso de Lima M. C., Düzgüneº N.: Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 1997, 272, 2382-2388.
  • 27. Snopczyński T., Góralczyk K., Czaja K., Struciński P., Hernik A., Korcz W., Ludwicki J. K.: Nanotechnology - possibilities and hazards. Rocz. Panstw. Zakl. Hig. 2009, 60, 101-111.
  • 28. Tanaka T., Decuzzi P., Cristofanilli M., Sakamoto J. H., Tasciotti E., Robertson F. M., Ferrari M.: Nanotechnology for breast cancer therapy. Biomed. Microdevices 2009, 11, 49-63.
  • 29. Theveno P. T., Cho J., Wavhal D., Timmons R. B., Tang L.: Surface chemistry influences cancer killing effect of TiO2 nanoparticles. 2008, 4, 226-236.
  • 30. Torchilin V. P.: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov. 2005, 4, 145-160.
  • 31. Wang M. D., Shin D. M., Simons J. W., Nie S.: Nanotechnology for targeted cancer therapy. Expert. Rev. Anticancer Ther. 2007, 7, 833-837.
  • 32. Wang X., Yang L., Chen Z. G., Shin D. M.: Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 2008, 58, 97-110.
  • 33. Wang Z., Chui W. K., Ho P. C.: Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm. Res. 2009, 26, 1162-1171.
  • 34. Wilczyński J. R., Kufelnicka M., Smolarz B., Nowińska A., Kulig A., Szpakowski M.: Czy gen MDR1 jest kluczem do skutecznej chemioterapii? Ginekol. Pol. 2006, 77, 476-484.
  • 35. Zhao Q. H., Zhang Y., Liu Y., Wang H. L., Shen Y. Y., Yang W. J., Wen L. P.: Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med. Oncol. 2009, 27, 203-212.

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.dl-catalog-a632e9ae-1e6b-49ce-b5d3-09534d8d0fbe
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.